In recent years, the Biostat Research and Development Center has strengthened its position as a CRO company and a strong partner in the Polish clinical research market. As a natural direction of development, the company has turned to foreign markets. Today, Biostat is involved in research and development projects in several European countries, while also establishing new contacts and partnerships in others.

For many years, Biostat has been one of the key players in the clinical research market in Poland. The company has already completed hundreds of commercial and non-commercial projects with partners such as Adamed, Astra Zeneca, Celon Pharma, Chiesi, Pfizer, Polpharma, Servier, Takeda, the Medical University of Warsaw, the Medical University of Wrocław, the Medical University of Gdańsk, the National Oncology Institute, the Jagiellonian University, the University Clinical Hospital in Opole, the Nicolaus Copernicus University in Toruń, the Silesian Centre for Heart Diseases, and the Institute of Hematology and Transfusion Medicine.

The company's high position in the domestic market has become an inspiration and catalyst for expanding its activities to foreign markets.

We are increasingly using the experience we have gained from conducting local clinical trials. Dynamic development, including in foreign markets, is crucial for Biostat's future. We think prospectively about increasing the number of projects conducted internationally , as well as developing the entire company through investments in research and development activities carried out in countries such as Germany, Austria, Hungary, Bulgaria, the Czech Republic, or Italy - says Edyta Klemba, Pharma Division Director at Biostat.

> Learn more about Biostat's clinical research services

The list of countries where Biostat will soon be able to conduct clinical trials is constantly growing. We are already involved in international projects in countries such as Austria, Slovenia, Greece, Sweden, Ukraine, Bulgaria, and Estonia.

The stable team and its diverse competencies, as well as the advanced technological potential, are the driving force behind Biostat's expansion beyond Poland. Our consistent strategy is already yielding visible results. Collaboration with solid foreign partners gives us even wider possibilities, as a result of which we can offer our services across the entire continent - emphasizes Rafał Piszczek, President of the Biostat Management Board.

• See the list of clinical studies conducted by Biostat

   

It is worth adding that Biostat's expansion into foreign markets includes not only the field of clinical research. In 2023, the Biostat group launched a version of the Medfile program for the Norwegian market. Medfile EDM is a software for managing electronic medical records and telemedicine services.